COMPARISON
Abaloparatide vs Octreotide
7 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Abaloparatide is authorised or registered in 5 and Octreotide in 10 of the 10 registers read. Abaloparatide: No trial states a phase. Octreotide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Abaloparatide | Octreotide | |
|---|---|---|
| Registered trials differs | 25 clinicaltrials.gov · 2026-10-03 | 344 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Tymlos openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2022-12-12 ema · 2026-10-03 | 2025-06-30 ema · 2026-10-03 |
| EU refused on differs | 2018-04-03 ema · 2026-10-03 | Not checked no record of "refusedOn" for octreotide |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for abaloparatide | 2022-12-02 ema · 2026-10-03 |
| ATC code differs | H05AA04 ema · 2026-10-03 | H01CB02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Abaloparatide | placebo | Octreotide | placebo |
|---|---|---|---|---|
| Nausea | 8.0% | 3.1% | 30.8% | 21.2% |
| Hypertension | 6.2% | 6.0% | 26.5% | 19.4% |
| Hypercalciuria | 9.7% | 8.9% | - | - |
| Dizziness | 9.4% | 5.5% | - | - |
| Nasopharyngitis | 8.8% | 8.5% | - | - |
| Arthralgia | 8.3% | 9.3% | - | - |
| Headache | 7.2% | 6.1% | - | - |
| Back pain | 7.1% | 8.2% | - | - |
| Upper respiratory tract infection | 6.9% | 7.8% | - | - |
| Influenza | 5.8% | 4.5% | - | - |
| Diarrhoea | - | - | 46.2% | 31.7% |
| Oedema peripheral | - | - | 34.9% | 19.6% |
| Asthenia | - | - | 33.3% | 20.9% |
| Fatigue | - | - | 29.8% | 27.7% |
| Rash | - | - | 28.8% | 14.1% |
| Decreased appetite | - | - | 28.5% | 15.2% |
| Dyspnoea | - | - | 25.9% | 9.1% |
| Anaemia | - | - | 24.3% | 9.1% |
Trial register Abaloparatide: 4 placebo-controlled trials; Octreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Abaloparatide side effects · Octreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Abaloparatide | Octreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.